Clinical trials: Non-Smoker
Non-squamous Non-small Cell Lung Cancer
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small…
- Trial name
- NCT02264990
- Testing
- Paclitaxel, Carboplatin, Cisplatin
- Where
- 140 sites in United States, Argentina and 18 more
- Volunteers
- 595 people
- Sponsor
- AbbVie
Non-Small-Cell Lung Cancer
A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
The purpose of this study is to compare the combination of erlotinib and pemetrexed versus either pemetrexed alone and erlotinib alone, in terms of progression-free survival (time until the objective worsening of the disease) in…
- Trial name
- NCT00550173
- Testing
- pemetrexed, erlotinib
- Where
- 29 sites in Brazil, China and 5 more
- Volunteers
- 247 people
- Sponsor
- Eli Lilly and Company
Healthy Subjects
A Study To Investigate The Metabolism Of GW876008 In Smokers Compared To Non-Smokers.
This study will investigate the effect of smoking on the metabolism of a single oral dose of GW876008.
- Trial name
- NCT00429728
- Testing
- GW876008
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
The purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT00409006
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 7 sites in China, South Korea and 1 more
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy
This study will evaluate the efficacy and safety of Tarceva in two groups of patients with non-small cell lung cancer who have not been pre-treated with chemotherapy.
- Trial name
- NCT02013206
- Testing
- erlotinib [Tarceva]
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Smoking, Tobacco Use
CSD210904: Study to Assess Actual Use of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in Current Adult Smokers
This is a multi-site, open-label, 8-week, prospective observational study, conducted at multiple sites geographically dispersed within the U.S. The purpose of this Actual Use Study (AUS) is to investigate how U.S.
- Conditions
- Smoking, Tobacco Use, Tobacco Smoking
- Trial name
- NCT05102786
- Testing
- 40007388, 40007385, 40007387
- Where
- 10 sites in United States
- Volunteers
- 1,180 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Non Small Cell Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants.
- Trial name
- NCT01017874
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company
Smoking, Healthy
Determination of Biomarkers of Exposure and Biomarkers of Potential Harm in Asian Adult Cigarette Smokers
The purpose of this study is to determine biomarkers of exposure to Harmful and Potentially Harmful Constituents (HPHCs) in Cigarette Smoke and cardiovascular-related biomarkers in smokers and non smokers.
- Trial name
- NCT02103751
- Where
- Japan
- Volunteers
- 1,069 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking, Tobacco Use Disorder
A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers
A randomized, double-blind, active-controlled, crossover, pilot study to evaluate the safety and efficacy of CigRx™ Lozenge, a dietary supplement, in daily smokers in temporarily reducing the desire to smoke
- Trial name
- NCT01262170
- Testing
- CigRx Lozenge, Tobacco Lozenge
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Rock Creek Pharmaceuticals, Inc.
Acute Inflammatory Response to Non-antigenic Stimulus
Phase 1a Study in Healthy Smokers to Investigate the Effect With MMI-0100 on Airway Inflammation in Induced Sputum After Challenge With Inhaled Lipopolysaccharide
A Phase 1a, randomized, placebo controlled, two-way crossover study is to determine the effect of inhaled MMI-0100 compared to placebo following LPS challenge on inflammatory markers.
- Trial name
- LPS (NCT02515396)
- Testing
- MMI-0100
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Moerae Matrix, Inc.
Chronic Periodontitis
Effect of Probiotics on Chronic Periodontitis in Smoker and Non- Smokers
Periodontitis is one of the most common chronic inflammatory disease with the etiology of bacterial plaque and is associated with a number of putative bacterial species.
- Trial name
- NCT02329353
- Testing
- Lactobacillus brevis CD2 Lozenges
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Next Gen Pharma India Pvt. Ltd.
Solid Malignancies
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
This study is being conducted to assess the safety, tolerability and PK of AZD1480 in patients with advanced solid malignancies.
- Trial name
- NCT01112397
- Testing
- AZD1480
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC)…
- Trial name
- NCT00606502
- Testing
- Pralatrexate, Erlotinib, Vitamin B12
- Where
- 47 sites in United States, Argentina and 4 more
- Volunteers
- 201 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Diabetes Type 2
Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes
Twelve smoking and twelve non-smoking subjects with Type 2 Diabetes Mellitus will be enrolled in this study to determine the effect of Technosphere® Insulin Inhalation Powder on insulin in the body during a clamp procedure.
- Trial name
- NCT00934414
- Testing
- Technosphere Insulin Inhalation Powder
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mannkind Corporation
Smoking
European Exposure Study
The current study was designed to determine the exposure of adult smokers and non-smokers to cigarette smoke constituents through evaluation of selected biomarkers of exposure.
- Trial name
- NCT01237912
- Where
- United Kingdom
- Volunteers
- 1,667 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Respiratory Disorders
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of 8 different formulations of investigational NTHI vaccine in current and former smokers, 50-70 years of age.
- Trial name
- NCT01678677
- Testing
- NTHI vaccine GSK2838500A (formulation 1), NTHI vaccine GSK2838501A (formulation 2), NTHI vaccine GSK2838502A (formulation 3)
- Where
- 3 sites in Belgium
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Disorders
Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine
This study will provide information regarding the sequential administration of two vaccines adjuvanted with AS01. The aim of this study is to understand immunogenicity and safety of NTHi-Mcat vaccine when administered…
- Trial name
- NCT03894969
- Testing
- GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E, Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
- Where
- 14 sites in Estonia, Finland and 3 more
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
This prospective, double-blind, randomized study will evaluate the safety and efficacy of two dose levels of erlotinib [Tarceva] on progression-free survival, response and disease control rates and overall survival in patients…
- Trial name
- NCT01183858
- Testing
- Erlotinib [Tarceva]
- Where
- 63 sites in China, Denmark and 7 more
- Volunteers
- 315 people
- Sponsor
- Hoffmann-La Roche